These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16521811)

  • 21. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
    Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
    Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention by life style intervention and medication. To run away from type 2 diabetes].
    Wepner U
    MMW Fortschr Med; 2004 Apr; 146(14):16. PubMed ID: 15344745
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cost-effective analysis of preventive treatment on diabetes].
    Hu Y; Chen SY; Wang JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):431-4. PubMed ID: 15231174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
    Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevention of type 2 diabetes: what is the evidence?
    Chiasson JL; Brindisi MC; Rabasa-Lhoret R
    Minerva Endocrinol; 2005 Sep; 30(3):179-91. PubMed ID: 16208307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Is type-2 diabetes mellitus preventable?].
    Jermendy G
    Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose].
    Scheen AJ
    Rev Med Liege; 2001 Oct; 56(10):727-30. PubMed ID: 11765586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevention of type 2 diabetes mellitus: recent advances.
    Younis N; Soran H; Farook S
    QJM; 2004 Jul; 97(7):451-5. PubMed ID: 15208433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Strategies for the prevention of elderly-onset type 2 diabetes mellitus].
    Toyonaga T; Araki E
    Nihon Rinsho; 2006 Jan; 64(1):140-3. PubMed ID: 16408462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
    Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
    Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
    Swanson A; Watrin K; Wilder L
    J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance.
    Smith-Marsh D
    Drugs Today (Barc); 2013 Aug; 49(8):499-507. PubMed ID: 23977667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.